Company Badge
USPTO Data Jan 1 1976 - Oct 20 2026
56 Patents
#173 in New York, NY
#388 in New York
#6,362 in US
#12,761 in the World
Chdi Foundation, Inc.
Forward Citations = 178
98 inventors:
New York, NY, United States of America
Chdi Foundation, Inc.
% Expired Patents = 1.8
CIPO Patents = 1
EPO Patents = 19
Forward Citations = 178
Loading Chart...
Loading Chart...
98 inventors (with patents filed for the assignee):
Celia Dominguez (52 out of 80 patents)
Michael Edward Prime (24 out of 25 patents)
Peter David Johnson (19 out of 31 patents)
4. Christopher John Brown (17 out of 26 patents)
5. Leticia M Toledo-Sherman (17 out of 17 patents)
6. John Wityak (16 out of 49 patents)
7. Jonathan Bard (14 out of 14 patents)
8. Christopher A Luckhurst (13 out of 13 patents)
9. Alan Findlay Haughan (13 out of 29 patents)
10. Daniel Clark-Frew (12 out of 12 patents)
11. Perla Breccia (12 out of 12 patents)
12. Andrew J Stott (12 out of 12 patents)
13. William Mitchell (10 out of 10 patents)
14. Roland W Bürli (10 out of 18 patents)
15. Stephen Martin Courtney (9 out of 52 patents)
Core Competencies:
Isoindolinone Compounds
Huntingtin Protein
Antisense Oligonucleotides
Rho Kinase Inhibitors
HTT Modulators
Imaging Agents
Zinc Finger Proteins
Kynurenine-3-Monooxygenase Inhibitors
Histone Deacetylase Inhibitors
Heterocyclic Compounds
Transglutaminase TG2 Inhibitors
Probes for Imaging
56 patents:
1. 12661415 - Isoindolinone compounds and imaging agents for imaging Huntingtin protein (2026-06-23),
2. 12551580 - Heterocyclic compounds and imaging agents for imaging Huntington protein (2026-02-17),
8. 12036292 - Heterobiaryl compounds and imaging agents for imaging huntingtin protein (2024-07-16),
Company Overview
Chdi Foundation, Inc. is a non-profit organization based in New York, dedicated to advancing research and development for Huntington's disease. The foundation focuses on innovative therapeutic approaches, including isoindolinone compounds, antisense oligonucleotides, and Rho kinase inhibitors, to target the underlying mechanisms of the disease. By leveraging cutting-edge technologies such as imaging agents and HTT modulators, Chdi aims to facilitate the discovery of effective treatments and improve the quality of life for those affected by Huntington's disease.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Chdi Foundation, Inc.. Retrieved from https://idiyas.com/company/chdi-foundation
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (CIPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
19 patents (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]